Kurdi et al. (2023) reported significant dysregulation of NFE2L2 in IDH-mutant astrocytomas, suggesting that NRF2 may interact with metabolic reprogramming driven by IDH1 mutations [107]. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).